Search
New York Paid Clinical Trials
A listing of 4503 clinical trials in New York actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
3613 - 3624 of 4503
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Location
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
New York is currently home to 4503 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Stroke Clinical Study
Recruiting
A clinical study for people that suffer with Stroke
Conditions:
Stroke
Featured Trial
Chronic Kidney Disease (CKD) Clinical Study
Recruiting
A clinical study for people that suffer with Chronic Kidney Disease (CKD)
Conditions:
Chronic Kidney Disease (CKD)
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
Recruiting
This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: Memorial Sloan Kettering Cancer Center-Commack, Commack, New York
Conditions: Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
Recruiting
This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: Memorial Sloan Kettering Cancer Center-Commack, Commack, New York
Conditions: Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery
Recruiting
The aim of this study is to find out the effects of TAK-330 compared with four-factor prothrombin complex concentrate (4F-PCC) as part of standard treatment other than Prothromplex Total for anticoagulation reversal in participants treated with Factor Xa inhibitors who require urgent surgery/invasive procedure.
The participant will be assigned by chance to either TAK-330 or SOC 4F-PCC as part of standard treatment before surgery.
Patients participating in this study will need to be hospitalize... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: Westchester Medical College, Valhalla, New York
Conditions: Coagulation Disorder
Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
Recruiting
This is a single group study of participants with advanced solid tumors who have not been cured by other treatments. It is the first time the drug will be used in humans, and will be in two parts.
The primary purpose of the parts are:
* Dose Escalation Part: To evaluate the safety and tolerability and to determine the maximum tolerated dose and the recommended dose for expansion of ifinatamab deruxtecan (I-DXd).
* Dose Expansion Part: To investigate the safety, tolerability and antitumor activ... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: Columbia University Medical Center, New York, New York
Conditions: Advanced Solid Tumor, Malignant Solid Tumor
68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
Recruiting
The study population consists of patients who undergo resection for somatostatin receptor-positive (SSTR-positive) CNS tumors, focusing on meningioma, and including esthesioneuroblastoma, hemangioblastoma, medulloblastoma, paraganglioma, pituitary adenoma, and SSTR-positive systemic cancers metastatic to the brain, such as small cell carcinoma of the lung. The study indication is to determine the diagnostic utility of 68Ga-DOTATATE PET/MRI in the diagnosis and management of patients with SSTR-po... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
12/18/2024
Locations: Weill Cornell Medicine, New York, New York
Conditions: CNS Tumors, Meningioma, Esthesioneuroblastoma, Hemangioblastoma, Medulloblastoma, Paraganglioma, Pituitary Adenoma
Safety and Durability of Sirolimus for Treatment of LAM
Recruiting
The MIDAS study aims to follow male and female LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of their clinical care. Adult female TSC patients may also enroll, with or without lung cysts.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Lymphangioleiomyomatosis
Predicting Responses to Exhausting, Prolonged, and Repeated Exercise Demands (PREPARED) for Heat
Recruiting
The overall goal of this project is to identify a work/rest cycle that allows for faster mission completion needed in emergency situations, compared to current Army heat guidance, while mitigating heat strain and neuromuscular fatigue. This project will determine the trade-off between faster mission completion and risk of heat strain and physical performance decrements. Completion of this project will allow military leaders to make informed decisions by understanding the impact of their choices... Read More
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
12/17/2024
Locations: Center for Research and Education in Special Environments, Buffalo, New York
Conditions: Hyperthermia, Fatigue; Heat
Dialectical Behavior Therapy for Justice-Involved Veterans
Recruiting
Dialectical Behavior Therapy for Justice-Involved Veterans (DBT-J) is a comprehensive, integrative program distinctively designed to address the range of mental health, substance use, case management, and legal needs of Veterans with current or ongoing criminal justice involvement. Data from two prior clinical trials attest to the program's feasibility and acceptability and preliminarily suggest participation in the program may yield meaningful improvements in risk for criminal behavior and reso... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2024
Locations: James J. Peters VA Medical Center, Bronx, NY, Bronx, New York
Conditions: Criminal Behavior, Criminal Recidivism, Psychosocial Functioning
Effects of Administration of SCFA in Rheumatoid Arthritis Inadequate Responders
Recruiting
This study is a pilot, proof of concept study to determine the effects of administering an oral short-chain fatty acid (SCFA) supplement to Rheumatoid Arthritis (RA) patients with inadequate response to methotrexate (MTX). The study will include up to 35 participants to obtain a sample size of at least 25 participants taking the oral supplement. The researchers hypothesize that oral SCFA will change the participants' gut microbiome and regulatory immune responses. Clinical data to assess for adv... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2024
Locations: NYU Langone Health Orthopedic Center, New York, New York
Conditions: Rheumatoid Arthritis
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Recruiting
This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel) for diffuse large B-cell lymphoma that has come back (recurrent) or that does not respond to treatment (refractory) or grade IIIb follicular lymphoma. Mosunetuzumab is a monoclonal antibody that may inter... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2024
Locations: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
Conditions: Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Follic Lymph to Diff Large B-Cell Lymphoma, Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
Recruiting
The aim of this study is to assess the safety, side effects and effectiveness of EP0031 in patients with advanced RET-altered malignancies
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Advanced Solid Tumor
COVID-19 Survivorship Registry
Recruiting
COVID-19 is associated with acute pulmonary and cardiac injury. To better understand the degree and severity of cardiopulmonary injury as well as short and long-term sequelae of COVID-19 infection, this study will perform longitudinal study in patients who had recent known diagnosis of COVID-19.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2024
Locations: NYU Langone Health, New York, New York
Conditions: Covid19
3613 - 3624 of 4503
When investigators decide to start a clinical trial, regulatory agencies such as the FDA and the IRB must review all plans and protocols to determine if the proposed trial is safe, ethical, and feasible. All clinical trials that recruit human participants have been reviewed and approved, and both non-paid and paid clinical research studies exist in New York.
After the study is approved the research team sets out to recruit volunteers who would like to participate in a clinical trial. Usually, volunteers are compensated for their time and travel expenses, and many paid clinical trials exist.
While one of the purposes of conducting clinical trials is testing the intervention on a large sample that would be representative of the general population, studies often have inclusion and exclusion criteria that outline who can and cannot participate. The inclusion criteria specifies the characteristics a participant must have in order to participate; for example, a liver cancer trial may have as an inclusion criteria that the participant must be a liver cancer patient.
On the other hand, the exclusion criteria outlines what type of individuals cannot participate; for example, a clinical trial testing a vitamin supplement in healthy individuals might want to disqualify participants who suffer from a serious condition and that can jeopardize the participant's ability to safely receive the experimental intervention. Due to safety concerns, pregnancy is often an exclusion criteria found in many studies.
In New York State, Columbia University and Mount Sinai Hospital are two of the largest research centers conducting clinical trials on a regular basis. As of this month, Columbia University is actively recruiting participants on at least 200 clinical trials from all phases, and Mount Sinai has over 500 active clinical trials.
Search Clinical Trials in New York by Condition
See All Conditions